Global Non-alcoholic Steatohepatitis Market 2016-2020 - Key Vendors are GSK, Novo Nordisk & Vivus - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Non-alcoholic Steatohepatitis Market 2016-2020" report to their offering.

The global NASH market is set to grow at a CAGR of 24.58% during the period 2016-2020.

One noteworthy trend in the market is the availability of patient assistance programs. Patient assistance programs offered by vendors, designed to fit individual needs regarding liver diseases, help them attain access to medications. AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Novo Nordisk are among the companies that offer patient assistance programs, offering solutions such as co-pay assistance and coupons.

According to the report, a key driver of market growth is an increasingly sedentary lifestyle. An unhealthy or sedentary lifestyle and the intake of high calorie food results in the accumulation of excess body fat, causing problems such as obesity, diabetes, cardiovascular problems, and liver disease, which are the associated conditions for NASH. This provides drug manufacturers with opportunities to manufacture new and effective drugs, thereby boosting the growth of the global NASH drugs market.

Further, the report states that one challenge that could severely impact market growth is the limited understanding of the disease's pathophysiology.

Key vendors:

• Arena Pharmaceuticals
• AstraZeneca
• F Hoffmann-La Roche
• GSK
• Novo Nordisk
• Vivus
  

Key questions answered in this report:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
  

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by dosage form

PART 09: Market segmentation by route of administration

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

For more information visit http://www.researchandmarkets.com/research/5bwxgs/global